Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Birefringent Imager

By Drug Discovery Trends Editor | February 19, 2010

FlowCAMThe new FlowCAM-XPL Birefringence Imaging and Analysis System from particle imaging and analysis instrumentation manufacturer Fluid Imaging Technologies, features cross-polarizing filters to reveal birefringent particles and cells that would otherwise remain invisible and undetectable or unclear under ordinary light conditions while boosting the image contrast vs. microscopy and other imaging techniques. To be unveiled at Pittcon 2010 booth #3312, the FlowCAM-XPL permits birefringent particles and cells to be automatically detected, imaged in high resolution, identified and differentiated from each other and from any non-birefringent particles and cells in a heterogeneous sample. Each image may be characterized based on dozens of measurement parameters in real time and saved along with its corresponding data set for in-depth analysis and collaborative review.

Developed for research scientists, laboratory managers, chemical engineers, food technologists, pharmaceutical chemists, water engineers and other professionals, the automated FlowCAM-XPL rapidly analyzes large samples of particles and cells far faster than with manually operated polarized light microscopes and without any slide preparation while yielding more precise, reliable and statistically significant data. Anisotropic particles such as solid and liquid crystals, sugars, starches, spices, fibers, polymers. ceramics, glass, pharmaceuticals and cells such as from muscle tissue, bone, Zebra and Quagga mussels, and butterfly wings ranging from .5um to 3mm in size are ideal for study on the new instrumentation.

Fluid Imaging Technologies


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50